chemist at the University of Oklahoma, Norman, who tracks the status of women and minority academic scientists. "If they can implement this, they can take a leadership role."
Harvard has long been criticized for its lack of diversity of science faculty in several disciplines, a situation made worse by Harvard's decentralized structure and its policy not to grant tenure to junior faculty, task force members said. Last year, for example, four women and 28 men in the school of arts and sciences received tenure offers. But the longsimmering issue did not come to a head until Summers's comments at a January workshop on women in science became public (Science, 28 January, p. 492) . The resulting outcry triggered a faculty vote of no confidence in Summers, who apologized repeatedly.
Hammonds's committee called for a senior provost for diversity and faculty development to work with Harvard deans to promote gender and ethnic equity. Harvard Provost Steven Hyman hopes to name that person-who likely would come from within Harvard-by September. The panel also proposed two funds, one to provide partial salary support for hiring scholars who increase diversity, the second to fund their labs. It said Harvard should begin to gather systematic data on faculty hiring, retention, and other measures and make the academic culture more family-friendly, through enhanced maternity leave practices, child-care support, and adjustments to the tenure clock. Grosz's panel urged the university to set up summer research programs for undergraduates, expand mentoring for all students, and provide research money for faculty juggling family and career.
Funding will not be a problem, Summers assured reporters, referring to the likelihood of "more resources allotted down the road." The biggest challenge Harvard faces, he said, is to overcome "issues of culture" within a university created "by men for men." Harvard is accepting comments on the report through the end of June, and academics around the country will be watching closely to see how well Harvard succeeds in transforming that culture.
-ANDREW LAWLER
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HIGHER EDUCATION
Gene Sequence Study Takes a Stab at Personalized Medicine
COLD SPRING HARBOR,NEW YORK-Since its beginning 15 years ago, the Human Genome Project was sold to the public and to Congress as a biomedical effort that would ultimately bring a person's unique DNA sequence data to bear on preventing and treating disease. Now the National Human Genome Research Institute (NHGRI), which led the U.S. public sequencing effort, is about to take a controversial step toward that goal.
At the Biology of Genomes meeting here last week, NHGRI's Eric Green announced that NHGRI will launch a pilot study in which researchers will sequence a portion of DNA from 400 seemingly healthy volunteers and try to discern each person's unique genetic risk factors for disease. They also plan to study the reactions of the volunteers to learning these results. " [NHGRI] is doing a reality check: Do people really want personalized medicine?" says Kelly Frazer, a genomicist at Perlegen Sciences in Mountain View, California.
The project, dubbed clinENCODE, promises to jump-start the transition from basic biological studies to clinical genomics, and that "is what the genome project is all about," says Richard Wilson, director of the sequencing center at Washington University in St. Louis, Missouri. But both Bruce Roe of the University of Oklahoma, Norman, and Evan Eichler of the University of Washington, Seattle, call the study as described a "terrible idea," in part because the sequence information from each individual may not provide much relevant biomedical information.
The 400 volunteers will donate DNA and undergo a battery of tests, including blood pressure measurements and white blood cell counts. Green and his colleagues will sequence the same 1% of each person's genome, regions that are already being intensely studied by basic researchers. Green's team plans to report back any variations spotted, including ones that may explain a person's current and future health status.
It's not clear how people will react to such results. Previous studies involving genetic testing for specific diseases have suggested that people can handle bad health news. Still, many fear that this genetic information will lead to discrimination by employers and insurance companies.
Many genome scientists argue that clin-ENCODE is not the best way to explore the future of personalized medicine. "There are so many genes whose function and link to disease is unknown that the information we are going to give is of dubious nature" and may overwhelm the participants, says Frazer. If the chief goal is to test how the public reacts to personalized genome information, then why not simply do surveys or present mock sequencing results rather than incur the expense of sequencing, she and others wonder.
Even if the study provides little biomedical data, it will still be worthwhile, contends Robert Waterston, a geneticist at the University of Washington, Seattle. 
